Communication with Stakeholders

General Meeting of Shareholders

Unlike many Japanese companies, which have fiscal years ending in March, Chugai’s fiscal year ends in December. As a result, we can avoid holding our general meeting of shareholders in June, which is the peak season for such meetings.

Notice of convocation for the general meeting of shareholders are normally sent out four weeks prior to the meeting date.

On the day of the general meeting of shareholders, we are undertaking various initiatives—including live streaming and real-time captioning of the proceedings—to enable a wider range of shareholders to better understand our business.

The 115th annual general meeting of shareholders was held on March 26, 2026. After the presentation of the business report, shareholders deliberated on agenda items concerning appropriation of surplus, election of directors, and revision of stock compensation system for directors. All agenda items were approved and passed by a majority.

Activity Performance

In 2025, we held meetings with institutional investors, securities analysts, and journalists to provide information on financial results and new products, and other events including a study session on data from an academic presentation on our in-house project. In addition, to promote understanding of our growth strategy, TOP I 2030, we held a tour of the new synthetic active pharmaceutical ingredient (API) manufacturing building FJ3 at the Fujieda Plant, which handles the production of APIs for small molecule and macrocyclic peptide drugs, as well as a briefing session on our open innovation strategy aimed at expanding our drug discovery engine, for the first time. At the annual Sustainability Meeting, Mr. Teramoto, speaking from his perspective as an independent outside director, explained Chugai’s key governance issues, including the role of the Board of Directors, enhancing the Board’s effectiveness, and sharing value with the capital markets, and engaged in a lively Q&A session with participating institutional investors and securities analysts. In addition, for individual investors, we released a video featuring a discussion between a management scholar and our CFO, aimed at explaining Chugai’s business model, proprietary technologies, and drug discovery strategy, including an objective perspective.

We believe that patients are not only important stakeholders but also partners in solving issues together. With the aim of “realization of advanced and sustainable patient-centric healthcare,” we are promoting communication to enhance mutual understanding throughout the entire company, including top management. In 2025, we held CHUGAI PHARMONY DAY 2025, an event also held the previous year to share and promote PHARMONY^* initiatives both inside and outside the Company, under the theme of “Further Expansion.” In addition to a presentation by a patient group representative on their thoughts regarding collaboration with companies, we shared specific examples from PHARMONY and Roche’s global initiatives for patient partnership. Moreover, we invited a healthcare professional to join the annual dialogue between Chugai’s CEO and patient groups, which has been held every year since 2020, and engaged in a discussion from diverse perspectives on the theme of “Patient Involvement in Healthcare.”

Due to the introduction of the Principles for Responsible Institutional Investors (Japan’s Stewardship Code) and Japan’s Corporate Governance Code, greater dialogue between companies and shareholders is required. Chugai has proactively established forums for ongoing discussions between investors and the management team to ensure a fuller exchange of opinions. We will continue measures to enhance face-to-face IR with management.

* A term coined by Chugai combining the words “Patients,” “Pharma” and “Harmony.” It refers collectively to activities conducted by Chugai to elicit the opinions of patients and their families with the aim of achieving mutual understanding and working toward shared value creation.